stockrowTelix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) EV/FCF
As of 5 November 2026, Telix Pharmaceuticals Limited (TLX) trades at a EV/FCF of −73.9×. Over the past ten years it has ranged from −73.9× (November 2026) to 32.9× (June 2026) — the current reading is the lowest in ten years.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 32.9× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TLX Telix Pharmaceuticals Limited | −73.9× |
| ELVN Enliven Therapeutics, Inc. compare | −31.3× |
| CELC Celcuity, Inc. compare | −18.4× |
| DNLI Denali Therapeutics Inc. compare | −7.2× |
| VRDN Viridian Therapeutics, Inc. compare | −7.0× |
| IDYA IDEAYA Biosciences, Inc. compare | −6.7× |
| VKTX Viking Therapeutics, Inc. compare | −5.1× |
| DYN Dyne Therapeutics, Inc. compare | −4.6× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 124× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))